Senicapoc (ICA-17043) Clinical Trials

Size	Price	Qty
5mg	USD 70
25mg	USD 170

Clinical Trials

Numerous Phase 1, Phase 2, and Phase 3 clinical trials sponsored by corporate and academic entities—including Icagen, Biossil Inc., Vejle Hospital, and the University of California, Davis—evaluate the therapeutic potential of Senicapoc. These studies encompass diverse hematologic, respiratory, neurological, and oncologic conditions, including sickle cell disease, asthma, dehydrated hereditary stomatocytosis, idiopathic pulmonary fibrosis, severe COVID-19-related acute respiratory distress, glioblastoma, and prodromal Alzheimer's disease. Currently, these trials exhibit varying recruitment statuses, including completed, recruiting, unknown, and terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07282210	RECRUITING	Sickle Cell Disease; Sickle Cell Anaemia; Sickle Cell Anemia	Biossil Inc.	2026-08-13	PHASE2
NCT06714123	RECRUITING	Pulmonary Fibrosis, Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis	Vejle Hospital	2025-08-01	PHASE2
NCT07284069	RECRUITING	Glioblastoma	Aarhus University Hospital	2026-03-01	EARLY_PHASE1
NCT04804241	RECRUITING	Mild Cognitive Impairment; Alzheimer Disease	University of California, Davis	2022-03-18	PHASE2
NCT04372498	COMPLETED	Dehydrated Hereditary Stomatocytosis	Boston Children's Hospital	2021-04-15	PHASE1; PHASE2
NCT04594668	UNKNOWN	ARDS, Human; COVID	University of Aarhus	2020-04-24	PHASE2
NCT00861185	COMPLETED	Exercise Induced Asthma	Icagen	2009-03	PHASE2
NCT00861211	COMPLETED	Atopic Asthma	Icagen	2008-10	PHASE2
NCT00040677	COMPLETED	Sickle Cell Disease; Sickle Cell Anemia	Icagen	2002-02	PHASE2
NCT00102791	TERMINATED	Sickle Cell Disease	Icagen	2005-02	PHASE3
NCT00294541	TERMINATED	Sickle Cell Disease; Sickle Cell Anemia	Icagen	2006-02	PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-17)

Check the Senicapoc (ICA-17043) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Senicapoc selectively binds to and inhibits the Gardos channel (KCa3.1), blocking calcium-activated potassium efflux and the accompanying loss of intracellular water. This inhibition prevents erythrocyte dehydration and hemolysis, thereby mitigating cellular sickling and maintaining microvascular tissue perfusion in clinical trial conditions such as sickle cell disease and hereditary stomatocytosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).